| Name | Title | Contact Details |
|---|
The Ideal Protein Method is medically designed & developed, being consistent with evidence-based guidelines for weight loss management and maintenance. It is a weight loss solution for the obese and overweight patient, including those with metabolic syndrome. Ideal Protein puts forward a proven, four-part method that enables safe, effective weight loss, with a healthy lifestyle approach and a structured maintenance program to sustain weight loss success. The method targets the root causes of weight gain by reversing the imbalance of insulin that occurs with the typical Western diet. A healthier lifestyle education is a key component of all phases of the Ideal Protein Weight Loss Method, which features personalized, one-on-one coaching and a diet plan to promote losing fat while maintaining lean muscle mass. For a hospital, medical group or private medical practice, the Ideal Protein Method is a comprehensive turnkey program with no costs for training and implementation, and no long-term commitment. Offered through healthcare practitioners, trained clinics and centers, the Ideal Protein Weight Loss Method and products are now available in more than 3,000 clinics and centers throughout North America. Research demonstrating the results of the Ideal Protein Weight Loss Method has been presented at leading medical conferences such as the 9th Annual Obesity Summit at the Cleveland Clinic and the Annual Scientific Meeting of the National Obesity Society. For information on Ideal Protein, please visit our website. For details about incorporating Ideal Protein into your medical practice, visit our practitioner information pages for Physicians and Pharmacists.
iHealth is dedicated to helping people lead healthier lives. Our goal is to make it as easy as possible for individuals of all ages to take a more active role in managing their health. We do this by designing and manufacturing innovative, consumer-friendly, mobile personal healthcare products that connect to the cloud. Our products are easy-to-use, making it simple for consumers to accurately measure, track and share a full range of health vitals. By automatically connecting the data through the cloud, consumers are able to see a more comprehensive view of their vitals and easily share information with healthcare professionals or loved ones. Our award-winning line of products include blood pressure monitors, blood glucose monitors, body analysis scales, pulse oximeters and activity and sleep trackers. All of our products sync directly with a free mobile app that makes monitoring, viewing, storing and sharing of health vitals simple and comprehensive.
Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients.
Canadian Generic Pharmaceutical Association is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.